Induction Chemotherapy Plus Concurrent Chemoradiation Therapy (ICCRT) Versus Concurrent Chemoradiation Therapy (CRT) in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

被引：0
|
作者：
Chang, J. [1 ]
Moon, S. [2 ]
Cho, K. [2 ]
Kim, T. [2 ]
Kim, H. [1 ]
Wu, H. [1 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[2] Res Inst & Hosp, Natl Canc Ctr, Proton Therapy Ctr, Gyeonggi Do, South Korea
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 84卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2012.07.1472
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S552 / S552
页数：1
相关论文
共 50 条
  • [21] Sequential Versus Concurrent Chemoradiation Therapy by Surgical Margin Status in Resected Non-Small Cell Lung Cancer
    Verma, Vivek
    Moreno, Amy C.
    Haque, Waqar
    Fang, Penny
    Lin, Steven H.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (05): : 508 - 516
  • [22] Comparison of chemoradiation and radiation therapy alone in patients with stage III unresectable non-small cell lung cancer
    Ahn, S
    Kim, Y
    Kim, K
    Na, K
    Kim, Y
    Bom, H
    Park, K
    LUNG CANCER, 2005, 49 : S164 - S165
  • [23] Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer
    Wang, Yu
    Zhang, Tao
    Wang, Jianyang
    Zhou, Zongmei
    Liu, Wenyang
    Xiao, Zefen
    Deng, Lei
    Feng, Qinfu
    Wang, Xin
    Lv, Jima
    Ma, Xiangyu
    Xue, Qi
    Wang, Jie
    Wang, Zhijie
    Bi, Nan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 116 (03): : 590 - 600
  • [24] Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study
    Wang, Chin-Chou
    Chiu, Li-Chung
    Ju, Jia-Shiuan
    Lin, Yu-Ching
    Fang, Yueh-Fu
    Yang, Cheng-Ta
    Hsu, Ping-Chih
    VACCINES, 2021, 9 (10)
  • [25] Concurrent chemoradiation therapy with weekly paclitaxel for locally advanced non-small cell lung cancer
    Kim, S
    Kim, S
    Shim, B
    Kim, C
    Song, S
    Ahn, M
    Jeong, Y
    Yoo, J
    Kim, H
    LUNG CANCER, 2005, 49 : S380 - S381
  • [26] CONCURRENT CHEMORADIATION TREATMENT FOR INOPERABLE, NONMETASTASIC, UNFIT NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
    Pons, F.
    Nadal, E. S.
    Plana, M.
    Palmero, R.
    Sole, J. M.
    Brao, I.
    Castany, R.
    Padrones, S.
    Arnaiz, M. M.
    Cardenal, F.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S75 - S75
  • [27] THE COMPARATIVE EFFECTIVENESS OF TREATMENTS AFTER CHEMORADIATION THERAPY (CRT) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): A NETWORK META-ANALYSIS (NMA)
    Dron, L.
    Harari, O.
    Fazeli, M. S.
    Zhang, Y.
    VALUE IN HEALTH, 2019, 22 : S56 - S56
  • [28] A phase I study of dasatinib with concurrent chemoradiation for stage III non-small cell lung cancer
    Khurshid, Humera
    Dipetrillo, Thomas
    Ng, Thomas
    Mantripragada, Kalyan
    Birnbaum, Ariel
    Berz, David
    Radie-Keane, Kathy
    Perez, Kimberly
    Constantinou, Maria
    Luppe, Denise
    Schumacher, Andrew
    Leonard, Kara
    Safran, Howard
    FRONTIERS IN ONCOLOGY, 2012, 2 : 7 - 11
  • [29] Predictive factors for survival and toxicity in stage III non-small cell lung cancer with concurrent chemoradiation
    Kim, Y.
    Ahn, S.
    Kim, Y.
    Kim, K.
    Oh, I.
    Chung, W.
    Nam, T.
    Yoon, M.
    Jeong, J.
    Song, J.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S319 - S319
  • [30] Lymphopenia as a predictor of survival in chemoradiation (CRT)-treated stage III non-small cell lung cancer (NSCLC).
    Yellu, Mahender
    Fakhrejahani, Farhad
    Ying, Jun
    Mierzwa, Michelle
    Malek, Ehsan
    Haque, Sulsal
    Sendilnathan, Arun
    Huth, Bradley Joseph
    Morris, John Charles
    Karim, Nagla Abdel
    Latif, Tahir
    Redmond, Kevin P.
    Barrett, William
    Videtic, Gregory M. M.
    Sadraei, Nooshin Hashemi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345